Efficacy News and Research

RSS

Study suggests physical activity influences depression and fatigue by increasing self-efficacy

Physical activity is known to reduce depression and fatigue in people struggling with chronic illness. A new study indicates that this effect stems from an individual's sense of mastery over - or belief in his or her ability to achieve - certain physical goals.

16 Dec 2009

Italian patent issued for NPM1 to test patients with AML

Xenomics, Inc., a developer of transrenal molecular diagnostics, announced today that a key Italian patent covering a unique diagnostic application with critical significance for patients with acute myeloid leukemia (AML) has issued.

16 Dec 2009

InSite Vision to advance new development candidate ISV-303

InSite Vision Incorporated, a company developing ophthalmic products for unmet eye care needs, today announced plans to advance new development candidate ISV-303, a topical anti-inflammatory product intended to reduce the pain and swelling associated with ocular surgery.

16 Dec 2009

Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company’s lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.

15 Dec 2009

Tarenflurbil drug does not appear to benefit Alzheimer’s patients

Although there were promising results in a phase 2 trial, patients with mild Alzheimer disease who received the drug tarenflurbil as part of a phase 3 trial did not have better outcomes on measures of cognitive decline or loss of activities of daily living compared to patients who received placebo, according to a study in the December 16 issue of JAMA.

15 Dec 2009

Positive results from study comparing exenatide once weekly to BYETTA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to BYETTA® (exenatide) injection taken twice daily, in patients with type 2 diabetes.

15 Dec 2009

Can-Fite BioPharma to commence Glaucoma Phase II clinical study in Israel

Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, announced on December 13 the initiation of the regulatory process for a Glaucoma Phase II clinical study in Israel. Leading Medical Centers in Israel will enroll 44 patients with Ocular Hypertension or Glaucoma for the first segment of the trial, who will be treated for 16 weeks with CF101 or placebo.

15 Dec 2009

University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer

GenSpera, Inc. announced today that the Institutional Review Board (IRB) at the University of Wisconsin, in Madison, WI, has approved a Phase I study of its target activated pro-drug, G-202, for the treatment of cancer. The FDA (US Food and Drug Administration) approved the study in September. GenSpera expects to enroll the first study patient early in the first quarter of 2010.

15 Dec 2009

Encouraging results from DAVANAT in combination with chemotherapies and biologics

Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute of Cancer Research is testing the ability of DAVANAT® to stop Galectin-3 from blocking the immune system’s action on cancer cells. Peer reviewed studies have demonstrated that Galectin-1 and Galectin-3 induce apoptosis (cell death) in immune system T cells (“Galectins,” Chapter 7, Wiley, 2008).

15 Dec 2009

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Celgene Corporation announced clinical data from an investigational Phase IIb, double-blind, placebo-controlled study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005). This was a 352-patient, multi-center study in which patients received either 10mg, 20mg or 30mg of apremilast twice per day (BID), or placebo.

15 Dec 2009

Enrolment for pivotal Phase II/III trial of C-Cure completed ahead of schedule

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today that it has completed, two months ahead of schedule, enrolment in the first stage of its pivotal Phase II/III trial of C-Cure, a unique stem cell therapy for heart failure.

15 Dec 2009

OU lab completes studies on new type of training technique

Bemben's lab at the university is currently only one of four labs outside of Japan that has been working with the KAATSU-Master training system, testing the effectiveness of reducing blood flow to exercising muscle.

15 Dec 2009

INS cites FDA-approved Totect antidote for anthracycline extravasations

The third edition of Infusion Nursing: An Evidence-Based Approach, published by the Infusion Nurses Society (INS), includes Totect(®), the only FDA-approved treatment for anthracycline extravasation. Anthracyclines are a group of chemotherapy medications including daunorubicin, doxorubicin, idarubicin and epirubicin that have been used in the treatment of various types of cancer since the early 1970s.

15 Dec 2009

Update on new clinical developments and other initiatives related to Ceplene

EpiCept Corporation today provided an update on new clinical developments and other initiatives related to Ceplene® (histamine dihydrochloride), the Company’s therapy approved in the European Union for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first remission.

15 Dec 2009

ProChon Biotech announces expansion of BioCart Cartilage Regeneration System study

ProChon Biotech, Ltd., an innovator of tissue regenerative technologies that are being developed to relieve pain and restore the mobility and quality of life for sufferers of articular cartilage injuries, today announced a significant expansion of its clinical study of the BioCart™ Cartilage Regeneration System.

15 Dec 2009

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company’s endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.

15 Dec 2009

Rexahn Pharmaceuticals and TheraTarget sign joint research collaboration agreement

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, and TheraTarget, Inc., a developer of innovative polymer therapeutics for the treatment of cancer, today announced the formation of a joint research collaboration agreement.

15 Dec 2009

SBi secures $30mm credit facility to fund business expansion

Small Bone Innovations, Inc. (SBi), a leading, privately held orthopedics company focused exclusively on technologies and treatments for the small bones & joints, has closed on a $30mm credit facility to fund accelerated business expansion and refinance existing indebtedness.

15 Dec 2009

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

Researchers at the Los Angeles Biomedical Research Institute (LA BioMed) expect to receive more than $4.5 million in grants from the American Recovery and Reinvestment Act (Recovery Act.), including nearly $1 million from the highly competitive Challenge Grant program for a study that seeks to reduce the number of children who die from Sudden Infant Death Syndrome, it was announced today.

15 Dec 2009

ALS TDI and Applied Proteomics join to identify protein biomarkers associated with ALS

The ALS Therapy Development Institute (ALS TDI) and Applied Proteomics, Inc. announced today that they have completed the first stage of a multi-year collaboration to identify and validate protein biomarkers associated with amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease).

15 Dec 2009

Efficacy News and Research

Study suggests physical activity influences depression and fatigue by increasing self-efficacy

Italian patent issued for NPM1 to test patients with AML

InSite Vision to advance new development candidate ISV-303

Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001

Tarenflurbil drug does not appear to benefit Alzheimer’s patients

Positive results from study comparing exenatide once weekly to BYETTA

Can-Fite BioPharma to commence Glaucoma Phase II clinical study in Israel

University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer

Encouraging results from DAVANAT in combination with chemotherapies and biologics

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Enrolment for pivotal Phase II/III trial of C-Cure completed ahead of schedule

OU lab completes studies on new type of training technique

INS cites FDA-approved Totect antidote for anthracycline extravasations

Update on new clinical developments and other initiatives related to Ceplene

ProChon Biotech announces expansion of BioCart Cartilage Regeneration System study

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

Rexahn Pharmaceuticals and TheraTarget sign joint research collaboration agreement

SBi secures $30mm credit facility to fund business expansion

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

ALS TDI and Applied Proteomics join to identify protein biomarkers associated with ALS

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News